Powehi Medical, a young spine startup focused on fixation systems and less rigid stability concepts, recently experienced a situation far more common in MedTech than many founders initially expect. After receiving its first European patent grant, a Swiss spine company filed an opposition at the European Patent Office (EPO).
This was not a lawsuit. For a startup, it can be more disruptive.
Why is it a challenge?
The European patent system contains a unique phase unfamiliar to many outside the industry:
- A patent is granted
- For 9 months, anyone can challenge it
- If an opposition is filed, the patent enters a suspended commercial reality until resolution
The patent exists legally, but the market behaves as if it might not. For startups, that uncertainty is often more damaging than a direct legal attack.
During the opposition period, which often lasts years, the company faces a structural freeze:
- Investors hesitate
- Strategic partners wait
- Customers avoid dependency on a technology that might disappear
- Competitors gain time without launching anything
At that stage, the problem is not legality. The problem is that nobody wants to be the first hospital depending on a technology that might still vanish two years later.
In practice, EPO oppositions frequently span several years, particularly when the case proceeds to appeal. The battlefield is not the courtroom. It is market confidence.
Why a Large Company Files an Opposition
Companies do not oppose patents for sport. They do it when a patent interferes with the future.
Typically one of three reasons exists:
- The concept overlaps with their future roadmap
- It blocks a strategic segment
- It threatens long-term commercial differentiation
In spine, it is most often the first. Large companies are frequently not trying to copy the technology today. They are ensuring that in eight years the startup cannot become a serious competitor.
The Strategic Reality of Innovation
For startups, a granted patent feels like protection. In MedTech, it is often only the beginning of validation. Oppositions are not purely legal tools. They are strategic time-management mechanisms. The goal is not immediate destruction. It is hesitation in the market.
In a market driven by surgeon trust, regulatory pathways, and capital cycles, time can be more valuable than winning the case.
In the end, surviving an opposition may strengthen a patent. But surviving the waiting period is what defines the company.
For Powehi Medical, the Real Test Was Time
For Powehi Medical, the opposition became more than a legal episode. What began as a milestone became uncertainty, and uncertainty became endurance. The patent survived not because the process was easy, but because the company kept moving while the procedure stood still. Over the years, new filings continued, development advanced, and the technology matured in parallel with the legal review. When the decision finally arrived, the patent was not only maintained, it was stronger.
The opposition did not stop the company; it tested whether it could exist long enough to matter.
####